Table 2:
FDA approved immunotherapies for pediatric oncology patients
| Drug | Trade Name | Pediatric Indication | Target | Type of Immunotherapy |
|---|---|---|---|---|
| Ipilimumab | Yervoy | Colorectal Cancer, Melnaoma | CTLA-4 | Monoclonal Antibody |
| Nivolumab | Opdivo | Colorectal Cancer | PD-1 | Monoclonal Antibody |
| Pembrolizumab | Keytruda | Hodgkin Lymphoma, Merkel Cell Carcinoma, Non-Hodgkin Lymphoma, Solid Tumors | PD-1 | Monoclonal Antibody |
| Blinatumomab | Blincyto | Acute Lymphoblastic Leukemia | C19, CD3 | Bi-specific T-cell engager |
| Tisagenlecleucel | Kymriah | Acute Lymphoblastic Leukemia, | CD19 | Chimeric Antigen Receptor T-cell |
| Gemtuzumab Ozogamicin | Mylotarg | Acute Myeloid Leukemia | CD33 | Antibody-drug conjugate |
| Avelumab | Bavencio | Merkel Cell Carcinoma | PD-L1 | Monoclonal Antibody |
| Dinutuximab | Unituxin | Neuroblastoma | GD2 | Monoclonal Antibody |
| Naxitamab-gqgk | Danyelza | Neuroblastoma | GD2 | Monoclonal Antibody |
Table contents obtained from National Cancer Institute: cancer.gov/about-cancer/treatment/drugs/childhood-cancer-fda-approved-drugs